The clinical success of re-challenging patients with a different TKI after progression is not just about hitting VEGF harder. TKIs are 'dirty' drugs that also target other kinases like MET and AXL, which are present on immune cells like tumor-associated macrophages (TAMs), providing a distinct immunomodulatory effect.

A specific macrophage population expressing SPP1 serves as a novel biomarker for true, tissue-level hypoxia. This allows researchers to distinguish drug-induced hypoxia from the 'pseudo-hypoxic' state caused by VHL deficiency, which has been a major challenge in studying RCC biology and treatment response.

Cancer should be viewed not just as rogue cells, but as a complex system with its own supply chains and communication infrastructure. This perspective shift justifies novel therapies like Zelenorstat, which aim to dismantle this entire operating system by cutting its power source.

Combination therapies in RCC are not immunologically equivalent. IO-IO (e.g., Ipi/Nivo) primarily promotes a CD8 T-cell response, associated with durable cures. In contrast, IO-TKI combinations stimulate B-cell and T-follicular helper cell responses, representing a fundamentally different mechanism of action within the tumor microenvironment.

The next major advance in adjuvant kidney cancer will be a biomarker to select who needs treatment. The key is developing a Minimal Residual Disease (MRD) test based on the epigenome (e.g., chromatin modifications) rather than just ctDNA mutations. This is because the critical biological signals in RCC are found in epigenetic regulation, not just the genome.

A pooled FDA analysis of four major kidney cancer trials found no "magic number" or threshold for tumor shrinkage that guarantees a favorable outcome. Instead, the relationship is linear: any incremental increase in tumor reduction correlates with better 36-month overall survival.

A sophisticated concern regarding the HIF-2 inhibitor belzutifan is its potential to diminish kidney cancer's antigenicity by reducing human endogenous retrovirus expression. While providing an early benefit, this could theoretically make tumors less responsive to subsequent immunotherapies, negatively impacting long-term outcomes—a critical consideration for sequencing.

The therapeutic effect of TKI-induced hypoxia is a double-edged sword. While it causes initial tumor necrosis and response, preclinical models suggest this same hypoxic environment can promote Epithelial-to-Mesenchymal Transition (EMT), a process that may lead to increased metastatic potential over the long term.

Unlike VEGF TKIs that primarily target the tumor vasculature, the HIF-2 inhibitor belzutifan has a direct anti-tumor cell effect. This mechanism may be uniquely effective against micrometastatic disease, following the logic of traditional chemotherapy. This distinction could explain its surprising success in the adjuvant setting where multiple VEGF TKIs have failed.